Mirum Pharmaceuticals, Inc. (MIRM)

NASDAQ: MIRM · Real-Time Price · USD

96.92

+0.43 (0.45%)

Apr 14, 2026, 3:27 PM EDT - Market open

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Livmarli Revenue	360.01M	213.30M
Livmarli Revenue Growth	68.78%	50.42%
Bile Acid Medicines Revenue	161.31M	123.11M
Bile Acid Medicines Revenue Growth	31.02%	232.03%
Total Product Revenue, Net	521.31M	336.41M
Total Product Revenue, Net Growth	54.96%	88.07%
License and Other Revenue	-	479.00K
License and Other Revenue Growth	-	-93.61%
Revenue (Total)	521.31M	336.89M
Revenue (Total) Growth	54.74%	80.76%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
License and Other Revenue	-	479.00K
License and Other Revenue Growth	-	-93.61%
United States - Product Revenue	401.55M	274.17M
United States - Product Revenue Growth	46.46%	86.89%
Rest of the World - Product Revenue	119.77M	62.24M
Rest of the World - Product Revenue Growth	92.44%	93.43%
Revenue (Total)	521.31M	336.89M
Revenue (Total) Growth	54.74%	80.76%

Updated Dec 31, 2025. Data Source: Fiscal.ai.